Generic Trulance Availability
Last updated on Apr 10, 2025.
Trulance is a brand name of plecanatide, approved by the FDA in the following formulation(s):
TRULANCE (plecanatide - tablet;oral)
-
Manufacturer: SALIX
Approval date: January 19, 2017
Strength(s): 3MG [RLD]
Is there a generic version of Trulance available?
No. There is currently no therapeutically equivalent version of Trulance available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trulance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ultra-pure agonists of guanylate cyclase C, method of making and using same
Patent 10,011,637
Issued: July 3, 2018
Inventor(s): Shailubhai Kunwar & Comiskey Stephen & Feng Rong & Bai Juncai & Zhang Ruoping & Jia Jun & Zhou Junfeng & Zhao Qiao & Zhang Guoqing
Assignee(s): SYNERGY PHARMACEUTICALS, INC.The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Patent expiration dates:
- June 5, 2034✓
- June 5, 2034
-
Ultra-pure agonists of guanylate cyclase C, method of making and using same
Patent 11,142,549
Issued: October 12, 2021
Inventor(s): Shailubhai Kunwar & Comiskey Stephen & Feng Rong & Bai Juncai & Zhang Ruoping & Jia Jun & Zhou Junfeng & Zhao Qiao & Zhang Guoqing
Assignee(s): Bausch Health Ireland LimitedThe invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Patent expiration dates:
- June 5, 2034✓
- June 5, 2034
-
Ultra-pure agonists of guanylate cyclase C, method of making and using same
Patent 11,319,346
Issued: May 3, 2022
Inventor(s): Shailubhai; Kunwar et al.
Assignee(s): Bausch Health Ireland Limited (Dublin, IE)The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Patent expiration dates:
- March 1, 2032✓
- March 1, 2032
-
Ultra-pure agonists of guanylate cyclase C, method of making and using same
Patent 11,834,521
Issued: December 5, 2023
Inventor(s): Shailubhai; Kunwar et al.
Assignee(s): Bausch Health Ireland Limited (Dublin, IE)The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Patent expiration dates:
- June 5, 2034✓
- June 5, 2034
-
Ultra-pure agonists of guanylate cyclase C, method of making and using same
Patent 12,146,003
Issued: November 19, 2024
Inventor(s): Shailubhai; Kunwar et al.
Assignee(s): Bausch Health Ireland Limited (Dublin, IE)The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Patent expiration dates:
- June 5, 2034✓
- June 5, 2034
-
Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Patent 7,041,786
Issued: May 9, 2006
Inventor(s): Shailubhai; Kunwar et al.
Assignee(s): Callisto Pharmaceuticals (New York, NY)A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
Patent expiration dates:
- January 30, 2028✓
- January 30, 2028
-
Formulations of guanylate cyclase C agonists and methods of use
Patent 9,610,321
Issued: April 4, 2017
Inventor(s): Comiskey Stephen & Feng Rong & Foss John & Shailubhai Kunwar
Assignee(s): SYNERGY PHARMACEUTICALS, INC.The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Patent expiration dates:
- September 15, 2031✓
- September 15, 2031✓
- September 15, 2031
-
Formulations of guanylate cyclase C agonists and methods of use
Patent 9,616,097
Issued: April 11, 2017
Inventor(s): Comiskey Stephen & Feng Rong & Foss John & Shailubhai Kunwar
Assignee(s): SYNERGY PHARMACEUTICALS, INC.The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Patent expiration dates:
- August 20, 2032✓
- August 20, 2032
-
Formulations of guanylate cyclase C agonists and methods of use
Patent 9,919,024
Issued: March 20, 2018
Inventor(s): Comiskey Stephen & Feng Rong & Foss John & Shailubhai Kunwar
Assignee(s): SYNERGY PHARMACEUTICALS, INC.The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Patent expiration dates:
- September 15, 2031✓
- September 15, 2031✓
- September 15, 2031
-
Formulations of guanylate cyclase C agonists and methods of use
Patent 9,925,231
Issued: March 27, 2018
Inventor(s): Comiskey Stephen & Feng Rong & Foss John & Shailubhai Kunwar
Assignee(s): SYNERGY PHARMACEUTICALS, INC.The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Patent expiration dates:
- September 15, 2031✓
- September 15, 2031
More about Trulance (plecanatide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (278)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Support group
- FDA approval history
- Drug class: guanylate cyclase-C agonists
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
